{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T10:30:32Z","timestamp":1773916232906,"version":"3.50.1"},"reference-count":85,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2010,2,1]],"date-time":"2010-02-01T00:00:00Z","timestamp":1264982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,2,1]],"date-time":"2010-02-01T00:00:00Z","timestamp":1264982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2010,2]]},"DOI":"10.1016\/j.biopha.2009.10.003","type":"journal-article","created":{"date-parts":[[2009,12,19]],"date-time":"2009-12-19T04:18:46Z","timestamp":1261196326000},"page":"140-145","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Therapeutic targets for persistent airway inflammation in refractory asthma"],"prefix":"10.1016","volume":"64","author":[{"given":"Patrick","family":"Murphy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tobias","family":"Hillman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karalasingam","family":"Rajakulasingam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2009.10.003_bib1","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1183\/09031936.98.12061322","article-title":"Costs of asthma according to the degree of severity","volume":"12","author":"Serra-Batlles","year":"1998","journal-title":"Eur Respir J"},{"key":"10.1016\/j.biopha.2009.10.003_bib2","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1183\/09031936.02.00232001","article-title":"Costs of asthma are correlated with severity: a 1-yr prospective study","volume":"19","author":"Godard","year":"2002","journal-title":"Eur Respir J"},{"key":"10.1016\/j.biopha.2009.10.003_bib3","unstructured":"British Guideline on the management of asthma. Supplement in Thorax. June 2009."},{"key":"10.1016\/j.biopha.2009.10.003_bib4","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1164\/ajrccm.156.3.9610046","article-title":"Bronchoscopic evaluation of severe asthma. Persistent inflammation associated with high dose glucocorticoids","volume":"156","author":"Wenzel","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.biopha.2009.10.003_bib5","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1183\/09031936.03.00261903","article-title":"The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma","volume":"22","author":"Abraham","year":"2003","journal-title":"Eur Respir J"},{"key":"10.1016\/j.biopha.2009.10.003_bib6","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/366421a0","article-title":"The Human IgE Network","volume":"366","author":"Sutton","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2009.10.003_bib7","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/icb.1996.60","article-title":"IgE, allergies and helminth parasites: A new perspective on an old conundrum","volume":"74","author":"Bell","year":"1996","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.biopha.2009.10.003_bib8","first-page":"160","article-title":"Studien \u00fcber die \u00dcberempf\u00edndlichkeit (Study on Hypersensitivity)","volume":"86","author":"Prausnitz","year":"1921","journal-title":"Zentralblatt fur Bakteriologie"},{"key":"10.1016\/j.biopha.2009.10.003_bib9","doi-asserted-by":"crossref","first-page":"75","DOI":"10.4049\/jimmunol.97.1.75","article-title":"Physiochemical properties of human reaginic antibody. IV. Presence of a unique immunoglobulin as a carrier of reaginic activity","volume":"97","author":"Ishizaka","year":"1966","journal-title":"J Immunol"},{"key":"10.1016\/j.biopha.2009.10.003_bib10","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1056\/NEJM198902023200502","article-title":"Association of asthma with serum IgE levels and skin-test reactivity to allergens","volume":"320","author":"Burrows","year":"1989","journal-title":"N Engl J Med"},{"key":"10.1016\/j.biopha.2009.10.003_bib11","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1093\/qjmed\/91.3.171","article-title":"Asthma and allergy \u2013 disorders of civilization?","volume":"91","author":"Holgate","year":"1998","journal-title":"QJM"},{"key":"10.1016\/j.biopha.2009.10.003_bib12","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/S0952-7915(05)80005-6","article-title":"Cytokine production by mast cells and basophils","volume":"3","author":"Galli","year":"1991","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.biopha.2009.10.003_bib13","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1172\/JCI110670","article-title":"Generation of leukotrienes by purified human lung mast cells","volume":"70","author":"MacGlashan","year":"1982","journal-title":"J Clin Invest"},{"key":"10.1016\/j.biopha.2009.10.003_bib14","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.4049\/jimmunol.129.6.2662","article-title":"Human lung mast cells: purification and characterisation","volume":"129","author":"Schulman","year":"1982","journal-title":"J Immunol"},{"key":"10.1016\/j.biopha.2009.10.003_bib15","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1067\/mai.2000.106485","article-title":"The diverse potential effector and immunoregulatory roles of mast cells in allergic disease","volume":"105","author":"Williams","year":"2000","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.biopha.2009.10.003_bib16","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1016\/S0140-6736(02)11679-5","article-title":"Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial","volume":"360","author":"Green","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2009.10.003_bib17","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1056\/NEJM199110103251504","article-title":"Relation between airway responsiveness and serum IgE in children with asthma and in apparently normal children","volume":"325","author":"Sears","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.biopha.2009.10.003_bib18","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1164\/ajrccm.160.6.9808146","article-title":"Interleukin-4 receptor in moderate atopic asthma. A phase I\/II randomized placebo-controlled Trial","volume":"160","author":"Borish","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.biopha.2009.10.003_bib19","doi-asserted-by":"crossref","first-page":"s6","DOI":"10.1164\/ajrccm.164.supplement_1.2103025","article-title":"Development of a monoclonal anti-Immunoglobulin E antibody (Omalizumab) for the treatment of allergic respiratory disorders","volume":"164","author":"Schulman","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.biopha.2009.10.003_bib20","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1185\/030079903125002171","article-title":"Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma","volume":"19","author":"Hochhaus","year":"2003","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.biopha.2009.10.003_bib21","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.4049\/jimmunol.158.3.1438","article-title":"Down-regulation of FceRI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody","volume":"158","author":"MacGlashan","year":"1997","journal-title":"J Immunol"},{"key":"10.1016\/j.biopha.2009.10.003_bib22","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1164\/rccm.200312-1651OC","article-title":"Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma","volume":"170","author":"Djukanovic","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.biopha.2009.10.003_bib23","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.jaci.2004.06.032","article-title":"Omalizumab-induced reductions in mast cell Fc\u025bRI expression and function","volume":"114","author":"Beck","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.biopha.2009.10.003_bib24","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.jaci.2003.10.003","article-title":"Omalizumab treatment downregulates dendritic cell Fc\u025bRI expression","volume":"112","author":"Prussin","year":"2003","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.biopha.2009.10.003_bib25","unstructured":"Novartis Europharm Ltd. Xolair 150mg powder and solvent for solution for injection. Summary of product characteristics, UK. 2005."},{"key":"10.1016\/j.biopha.2009.10.003_bib26","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1164\/ajrccm.155.6.9196082","article-title":"The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects","volume":"155","author":"Fahy","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.biopha.2009.10.003_bib27","doi-asserted-by":"crossref","unstructured":"Walker S, Monteil M, Phelan K, et al. Anti-IgE for chronic asthma in adults and children. Cochrane Database Syst Rev 2006, Issue 1. J Wiley and Sons, Ltd. Chichester, UK.","DOI":"10.1002\/14651858.CD003559.pub3"},{"key":"10.1016\/j.biopha.2009.10.003_bib28","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1398-9995.2004.00772.x","article-title":"Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE","volume":"60","author":"Humbert","year":"2005","journal-title":"Allergy"},{"key":"10.1016\/j.biopha.2009.10.003_bib29","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1006\/pulp.1995.1004","article-title":"The effects of Tumour Necrosis Factor-alpha on mediator release from human lung","volume":"8","author":"Hughes","year":"1995","journal-title":"Pulm Pharmacol"},{"key":"10.1016\/j.biopha.2009.10.003_bib30","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/0091-6749(91)90149-I","article-title":"Increased secretion of Tumor Necrosis Factor-alpha and interleukin-6 by alveolar macrophages consecutive to the development of the late asthmatic reaction","volume":"88","author":"Gosset","year":"1991","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.biopha.2009.10.003_bib31","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1136\/thorax.57.9.774","article-title":"Effects of inhaled Tumor Necrosis Factor-\u03b1 in subjects with mild asthma","volume":"57","author":"Thomas","year":"2002","journal-title":"Thorax"},{"key":"10.1016\/j.biopha.2009.10.003_bib32","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1056\/NEJMoa050580","article-title":"Evidence of a role of Tumor Necrosis Factor-\u03b1 in refractory asthma","volume":"354","author":"Berry","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.biopha.2009.10.003_bib33","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1136\/thx.2005.045260","article-title":"Tumour Necrosis Factor (TNF-\u03b1) as a novel therapeutic target in symptomatic corticosteroid dependent asthma","volume":"60","author":"Howarth","year":"2005","journal-title":"Thorax"},{"key":"10.1016\/j.biopha.2009.10.003_bib34","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1146\/annurev.immunol.19.1.163","article-title":"Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?","volume":"19","author":"Feldmann","year":"2001","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.biopha.2009.10.003_bib35","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0140-6736(02)08215-6","article-title":"Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial","volume":"359","author":"Braun","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2009.10.003_bib36","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1164\/rccm.200601-072OC","article-title":"The effects of a monoclonal antibody directed against Tumour Necrosis Factor-alpha in asthma","volume":"174","author":"Erin Em","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.biopha.2009.10.003_bib37","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1136\/thx.2007.086314","article-title":"The role of a soluble Tnf-\u00c1 receptor fusion protein (Etanercept) in corticosteroid-refractory asthma: A double blind. Randomised placebo-controlled trial","volume":"63","author":"Morjaria","year":"2008","journal-title":"Thorax"},{"key":"10.1016\/j.biopha.2009.10.003_bib38","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/BF00918968","article-title":"Molecular mechanism of methotrexate action in inflammation","volume":"16","author":"Cronstein","year":"1992","journal-title":"Inflammation"},{"key":"10.1016\/j.biopha.2009.10.003_bib39","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/0140-6736(90)91659-X","article-title":"Randomised, double blind, placebo controlled trial of methotrexate in steroid dependent-asthma","volume":"336","author":"Shiner","year":"1990","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2009.10.003_bib40","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/S0954-6111(98)90355-9","article-title":"Management of steroid-dependent asthma with methotrexate a meta-analysis of randomized clinical trials","volume":"92","author":"Aaron","year":"1998","journal-title":"Respir Med"},{"key":"10.1016\/j.biopha.2009.10.003_bib41","doi-asserted-by":"crossref","first-page":"353","DOI":"10.7326\/0003-4819-114-5-353","article-title":"Lack of benefit of methotrexate in severe, steroid-dependent asthma","volume":"114","author":"Erzurum","year":"1991","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.biopha.2009.10.003_bib42","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1136\/thx.46.12.936","article-title":"Pneumocystis carinii pneumonia as a complication of methotrexate treatment of asthma","volume":"46","author":"Kuitert","year":"1991","journal-title":"Thorax"},{"key":"10.1016\/j.biopha.2009.10.003_bib43","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1136\/thx.50.11.1221","article-title":"Fatal varicella zoster infection in a severe steroid dependent asthmatic patient receiving methotrexate","volume":"50","author":"Morice","year":"1995","journal-title":"Thorax"},{"key":"10.1016\/j.biopha.2009.10.003_bib44","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1136\/thx.50.4.422","article-title":"Fatal chickenpox pneumonia in an asthmatic patient on oral steroids and methotrexate","volume":"50","author":"Gatnash","year":"1995","journal-title":"Thorax"},{"key":"10.1016\/j.biopha.2009.10.003_bib45","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1080\/21548331.1987.11703269","article-title":"Current status of liver transplantation","author":"Sabesin","year":"1987","journal-title":"Hosp Prac"},{"key":"10.1016\/j.biopha.2009.10.003_bib46","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1146\/annurev.iy.10.040192.002511","article-title":"Cyclosporin A, FK506 and Rapamycin: pharmacological probes of lymphocyte signal transduction","volume":"10","author":"Sigal","year":"1992","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.biopha.2009.10.003_bib47","first-page":"65","article-title":"Cyclosporin A reduces T lymphocyte activity and improves airway hyperresponsiveness in corticosteroid-dependent chronic severe asthma","volume":"75","author":"Fukuda","year":"1995","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.biopha.2009.10.003_bib48","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/0140-6736(92)91646-P","article-title":"Trial of cyclosporin in corticosteroid-dependent chronic severe asthma","volume":"339","author":"Alexander","year":"1992","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2009.10.003_bib49","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1164\/ajrccm.153.2.8564089","article-title":"Double-blind, placebo-controlled study of cyclosporin A as a corticosteroid-sparing agent in corticosteroid-dependent asthma","volume":"153","author":"Lock","year":"1996","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.biopha.2009.10.003_bib50","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/j.1398-9995.1991.tb00590.x","article-title":"Cyclosporin for steroid-dependent asthma","volume":"46","author":"Szczeklik","year":"1991","journal-title":"Allergy"},{"key":"10.1016\/j.biopha.2009.10.003_bib51","unstructured":"Injectable gold for rheumatoid arthritis. Cochrane database of systematic reviews 2000, issue 2: CD000520."},{"key":"10.1016\/j.biopha.2009.10.003_bib52","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/j.1365-2567.2007.02679.x","article-title":"Auranofin blocks interleukin-6 signalling by inhibiting phosphrylation of JAK1 and STAT3","volume":"122","author":"Kim","year":"2007","journal-title":"Immunology"},{"key":"10.1016\/j.biopha.2009.10.003_bib53","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/S1567-5769(01)00050-9","article-title":"Mechanism of action of disease modifying anti-rheumatic agent gold sodium thiomalate (GSTM)","volume":"1","author":"Mangalam","year":"2001","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.biopha.2009.10.003_bib54","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1136\/thx.49.7.649","article-title":"Effect of oral gold compound, auranofin on nonspecific bronchial hyper responsiveness in mild asthma","volume":"49","author":"Honma","year":"1994","journal-title":"Thorax"},{"key":"10.1016\/j.biopha.2009.10.003_bib55","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1136\/thx.47.5.349","article-title":"Auranofin in the treatment of steroid dependent asthma: a double-blind study","volume":"47","author":"Nierop","year":"1992","journal-title":"Thorax"},{"key":"10.1016\/j.biopha.2009.10.003_bib56","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/0091-6749(87)90202-8","article-title":"Chrysotherapy in the treatment of corticosteroid dependent asthma","volume":"79","author":"Klaustermyer","year":"1987","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.biopha.2009.10.003_bib57","first-page":"132","article-title":"Gold salt in the treatment of bronchial asthma \u2013 a double-blind study","volume":"40","author":"Muranaka","year":"1978","journal-title":"Ann Allergy"},{"key":"10.1016\/j.biopha.2009.10.003_bib58","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S0091-6749(96)70156-2","article-title":"A placebo-controlled multicenter study of auranofin in the treatment of patients with corticosteroid-dependent asthma: Auranofin Multicenter Drug Trial","volume":"98","author":"Bernstein","year":"1996","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.biopha.2009.10.003_bib59","unstructured":"Gold as an oral corticosteroid sparing agent in stable asthma. Cochrane database of systematic reviews 2001, issue 2: CD002985."},{"key":"10.1016\/j.biopha.2009.10.003_bib60","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1126\/science.7063880","article-title":"Bronchoconstrictor effects of leukotriene C in humans","volume":"216","author":"Weiss","year":"1982","journal-title":"Science"},{"key":"10.1016\/j.biopha.2009.10.003_bib61","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJM199009063231006","article-title":"Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases","volume":"323","author":"Lewis","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.biopha.2009.10.003_bib62","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/0140-6736(93)91073-U","article-title":"Leukotriene E(4) and granulocytic infiltration into asthmatic airways","volume":"341","author":"Laitinen","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2009.10.003_bib63","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1164\/ajrccm\/143.5_Pt_1.1015","article-title":"Attenuation of inhaled allergen-induced airway microvascular leakage and airflow obstruction in guinea pigs by a 5-lipoxygenase inhibitor (A-63162)","volume":"143","author":"Hui","year":"1991","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.biopha.2009.10.003_bib64","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0090-6980(83)90101-6","article-title":"Effects of leukotrienes C4 and D4 on glycoprotein and lysozyme secretion by human bronchial mucosa","volume":"25","author":"Coles","year":"1983","journal-title":"Prostaglandins"},{"key":"10.1016\/j.biopha.2009.10.003_bib65","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1136\/thx.52.4.348","article-title":"Attenuation of early and late phase allergen-induced bronchoconstriction in asthmatic subjects by a 5-lipoxygenase activating protein antagonist, BAYx 1005","volume":"52","author":"Hamilton","year":"1997","journal-title":"Thorax"},{"key":"10.1016\/j.biopha.2009.10.003_bib66","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/j.1398-9995.2006.01007.x","article-title":"Effect of montelukast on lung function in asthma patients with allergic rhinitis: analysis from the COMPACT trial","volume":"61","author":"Price","year":"2006","journal-title":"Allergy"},{"key":"10.1016\/j.biopha.2009.10.003_bib67","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1136\/bmj.324.7353.1545","article-title":"Anti-leukotrienes as add-on therapy to inhaled glucocorticoids in patients with asthma: systematic review of current evidence","volume":"324","author":"Ducharme","year":"2002","journal-title":"BMJ"},{"key":"10.1016\/j.biopha.2009.10.003_bib68","series-title":"Cochrane Database Syst Rev","article-title":"Long-acting beta2-agonists versus antileukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma","author":"Ram","year":"2005"},{"key":"10.1016\/j.biopha.2009.10.003_bib69","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1056\/NEJMoa070013","article-title":"Randomised comparison of strategies for reducing treatment in mild persistent asthma","volume":"356","author":"Peter","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.biopha.2009.10.003_bib70","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/1465-9921-8-67","article-title":"Salmeterol plus fluticasone propionate versus fluticasone propionate plus montelukast: a randomised controlled trial investigating the effects on airway inflammation in asthma","volume":"8","author":"Pavord","year":"2007","journal-title":"Resp Res"},{"key":"10.1016\/j.biopha.2009.10.003_bib71","doi-asserted-by":"crossref","unstructured":"The American Lung Association Asthma Clinical Research Centres. Clinical trial of low dose theophylline and monteleukast in patients with poorly controlled asthma. Am J Respir Crit Care Med 2007;175:235\u201342.","DOI":"10.1164\/rccm.200603-416OC"},{"key":"10.1016\/j.biopha.2009.10.003_bib72","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1183\/09031936.02.00283202","article-title":"Scientific rationale for inhaled combination therapy with long acting \u03b22-agonists and corticosteroids","volume":"19","author":"Barnes","year":"2002","journal-title":"Eur Respir J"},{"key":"10.1016\/j.biopha.2009.10.003_bib73","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1378\/chest.130.3.741","article-title":"Montelukast treatment attenuates the increase in myofibroblasts following low-dose allergen challenge","volume":"130","author":"Kelly","year":"2006","journal-title":"Chest"},{"key":"10.1016\/j.biopha.2009.10.003_bib74","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1183\/09031936.04.00008104","article-title":"Failure of monteleukast to reduce sputum eosinophilia in high dose corsticosteroid dependent asthma","volume":"25","author":"Jayaram","year":"2005","journal-title":"Eur Respir J"},{"key":"10.1016\/j.biopha.2009.10.003_bib75","doi-asserted-by":"crossref","unstructured":"Van Schalkwyk E, Strydom K, Williams Z, et al. Roflumilast, an oral, once daily phosphodiesterase 4 inhibitor, attenuates allergen-induced asthmatic reactions. J Allergy Clin Immunol 2005;116:292\u2013298.","DOI":"10.1016\/j.jaci.2005.04.023"},{"key":"10.1016\/j.biopha.2009.10.003_bib76","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1111\/j.1476-5381.1995.tb13278.x","article-title":"Differential effects of non-selective and selective phosphodiesterase inhibitors on human eosinophil functions","volume":"114","author":"Hatzelmann","year":"1995","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.biopha.2009.10.003_bib77","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/j.1365-2222.1995.tb01110.x","article-title":"Cyclic nucleotide phosphodiesterase isoenzyme activities in human alveolar macrophages","volume":"25","author":"Tenor","year":"1995","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.biopha.2009.10.003_bib78","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1124\/jpet.103.059097","article-title":"Anti-inflammatory potential of the selective phosphodiesterase 4 inhibitor N-(3,5-dichloro-pyrid-4-yl)-[1-(4-fluorobenzyl)-5-hydroxy-indole-3-yl]-glyoxylic acid amide (AWD 12-281), in human cell preparations","volume":"308","author":"Draheim","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.biopha.2009.10.003_bib79","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/S0022-3565(24)29538-0","article-title":"In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE-4 inhibitor","volume":"297","author":"Bundschuh","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.biopha.2009.10.003_bib80","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.jaci.2005.04.023","article-title":"Roflumilast, an oral posphodiesterase \u2013 4 inhibitor, attenuates allergic induced asthmatic reaction","volume":"116","author":"Van Schalkwyk","year":"2005","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.biopha.2009.10.003_bib81","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1159\/000095677","article-title":"Roflumilast a phosphodiesterase \u2013 4 inhibitor reduces airway hyperresponsiveness after allergen challenge","volume":"74","author":"Louw","year":"2007","journal-title":"Respir"},{"key":"10.1016\/j.biopha.2009.10.003_bib82","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S1081-1206(10)61065-4","article-title":"Efficacy and safety of Rofluimlast in the treatment of asthma","volume":"96","author":"Bateman","year":"2006","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.biopha.2009.10.003_bib83","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1183\/09031936.04.00102504","article-title":"CCR4 ligands are upregulated in the airways of atopic asthmatics after segmental allergen challenge","volume":"23","author":"Pilette","year":"2004","journal-title":"Eur Respir J"},{"key":"10.1016\/j.biopha.2009.10.003_bib84","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1056\/NEJMoa073600","article-title":"A chitinase-like protein in the lung and circulation of patients with severe asthma","volume":"357","author":"Chupp","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.biopha.2009.10.003_bib85","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1056\/NEJMoa0708801","article-title":"Effect of the variation of CHI3L1 on serum YKL-40 level, risk of asthma and lung function","volume":"385","author":"Ober","year":"2008","journal-title":"N Engl J Med"}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332209002236?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332209002236?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T10:45:20Z","timestamp":1760093120000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332209002236"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2]]},"references-count":85,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,2]]}},"alternative-id":["S0753332209002236"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2009.10.003","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2010,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic targets for persistent airway inflammation in refractory asthma","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2009.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}